Overactive Bladder Treatment Market By Drug Class (Anti-Cholinergic Drugs, Beta-3 adrenergic drugs, Botox, Others), By Diseases type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The overactive bladder treatment market valued for $2,426.40 million in 2021 and is estimated to reach $3,465.22 million by 2031, exhibiting a CAGR of 3.6% from 2022 to 2031.
Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.
Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder.
For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market.In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.
Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.
In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region.
In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period.Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth.
The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the overactive bladder treatment market analysis from 2021 to 2031 to identify the prevailing overactive bladder treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the overactive bladder treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global overactive bladder treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
Anti-Cholinergic Drugs
Beta-3 adrenergic drugs
Botox
Others
By Diseases type
Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Korea
Rest of LAMEA
Key Market Players
AbbVie Inc.
Dr. Reddy’s Laboratories Ltd.
Teva Pharmaceutical Industries Limited
Cipla Ltd
Lupin
Sumitomo Pharma Co., Ltd
Astellas Pharma Inc.
Sun Pharmaceutical Industries Ltd.
Pfizer Inc.
Alembic Pharmaceuticals Limited
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook